#ES­MO22: Trail­ing Roche’s Tecen­triq, im­mune check­point ther­a­pies meet un­treat­ed liv­er can­cer with mixed re­sults

PARIS — In 2020, Roche’s Tecen­triq, a PD-L1 in­hibitor, got an FDA nod in com­bi­na­tion with Avastin for un­treat­ed ad­vanced liv­er can­cer, be­com­ing the first im­mune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER